Comparative cardiovascular efficacy of antidiabetic therapies in type 2 diabetes: a systematic review and network meta-analysis of randomized trials.
Two common diabetes drugs tackle different heart problems: GLP-1 drugs prevent strokes and early death, while SGLT2 drugs prevent heart failure—knowing which does what helps doctors pick the right one.
Network meta-analysis of 133 RCTs (289,558 T2DM patients) shows GLP-1 receptor agonists significantly reduce cardiovascular mortality (RR=0.85) and stroke (RR=0.83) with high-certainty evidence, while SGLT2 inhibitors most strongly reduce heart failure (RR=0.64) and CV hospitalization (RR=0.72), providing definitive head-to-head hierarchy for clinical prescribing.
What the study was
- Study design
- meta_analysis
- Category
- cardiovascular_metabolic
- Maturity
- clinical
- Journal
- Diabetology & Metabolic Syndrome
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.